# Diabetes Diabetes

### CTLA-4 Ig Study

Form CTL07

1 JAN 2008	
Version 1.0	
Page 1 of 3	

TrialNef	rialNet STUDY DRUG ADMINISTRATION FORM					Version 1.0 Page 1 of 3		
Site:	Screening ID:		Rand. Number:		Letters:			
Complete this form during the Baseline Visit and the following visits.								

Complete this form during the Baseline Visit and the following visits.						
A. VISIT INFORMATION						
1. Visit Date: $\frac{1}{DAY} = \frac{1}{MONTH}$						
2. For which visit is this form being completed? (check one)				ıĸ		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Visit 14 Visit 15 Visit 16 Visit 17 Visit 18 Visit 19 Visit 20	☐ 21 ☐ 22 ☐ 23 ☐ 24 ☐ 25 ☐ 26	Visit 21 Visit 22 Visit 23 Visit 24 Visit 25 Visit 26			
B. STUDY DRUG ADMINISTRATION CRITERIA						
1. If FEMALE with reproductive or childbearing potential, was the pregn	ancy test result	positive?	Y	N		
If YES, STOP here, DO NOT administer study drug and complete a Pregnancy Confirmation Form (CTL14) REMINDER: A pregnancy test MUST be completed before administering study drug						
2. Has the subject had a febrile illness within the last ten days?			Y	N		
3. Were there any grade 3 or greater problems with the previous infusion?						
4. Does the previous CBC indicate grade 3 or greater lymphopenia?			Y	N		
5. If EBV seronegative, was the previous EBV PCR result positive?						
All ANSWERS MUST BE NO.  If YES, STOP here, DO NOT administer study drug.  Complete an Adverse Event Report Form (CTL13) if ≥ Grade 2 severity.						
	,	<u> </u>				
C. STUDY DOSING INFORMATION  1. Participant Weight						
a. At previous visit kg or						
b. At current visitkg or						
2. Is the current weight 10% different than the previous visit weight?						
If YES, use the current weight to calculate the dosage.						
3. Record weight used to determine dosage:	k	g or		lbs		
4. What is the dose? (Dose = Dosing weight x 10mg/kg)						
D. STUDY DRUG ADMINISTRATION						
1. Time infusion started:						
2. Time infusion stopped:						

On all questions write "?" if the desired information is currently unavailable, but is being checked and will be known in future updates. Write "\*" if the desired information is permanently unavailable (i.e. will not be known in any future updates).



#### CTLA-4 Ig Study

Form CTL07 01 JAN 2008

STUDY DRUG ADMINISTRATION FORM Version 1.0 Page 2 of 3 Screening ID: Letters: Visit Date: Site: D. STUDY DRUG ADMINISTRATION (Continued) 3. Was the full dose infused? Y N If NO, a. Record dose of drug infused: b. Describe the circumstances: If due to an Adverse Event, record in Section G and complete an Adverse Event Report Form (**CTL13**) if ≥ Grade 2 severity. E. VITAL SIGNS **NOTE\*:** DO NOT administer study drug if the patient is febrile pre-infusion. **Blood Pressure** d. Heart e. Respiratory a. Systolic: b. Diastolic: c. Temperature\*: rate: rate: 1. Pre-Infusion\* \_\_\_ . \_\_ °C or Time: \_\_:\_ (24 hour clock) mm Hg mm Hg breaths/min bpm \_\_\_. \_ °C or 2. 15 min. Time: \_\_\_: \_\_ mm Hg mm Hg breaths/min bpm \_\_\_ . \_\_ °C or 3. End of Infusion breaths/min Time: \_\_\_:\_\_\_ mm Hg mm Hg bpm \_\_\_. \_ °C or 4. 15 min Post Infusion breaths/min Time: \_\_\_:\_\_\_ mm Hg mm Hg bpm \_\_ . \_\_ °C or 5. 30 min Post Infusion Time: \_\_\_:\_\_\_ mm Hg mm Hg bpm breaths/min . °C or 6. 60 min Post Infusion Time: \_\_\_:\_\_\_ mm Hg mm Hg breaths/min bpm F. ACETAMINOPHEN AND DIPHENHYDRAMINE ADMINISTRATION 1. Was Acetaminophen given to the participant? N If YES, a. Dose (if applicable): b. Time dose given (if applicable): (24 hour clock) 2. Was Diphenhydramine given to the participant? N If YES. a. Dose (if applicable): \_ . \_\_\_ mg b. Time dose given (if applicable): \_ (24 hour clock) N 3. Were any other medications given? Y If YES, a. Specify: b. Dose (if applicable): \_ . \_\_\_ mg c. Time dose given (if applicable): Time: \_\_\_: \_\_ (24 hour clock)

On all questions write "?" if the desired information is currently unavailable, but is being checked and will be known in future updates. Write "\*" if the desired information is permanently unavailable (i.e. will not be known in any future updates).

## CTLA-4 Ig Study

Form CTL07

TrialNet	,	STUDY DRUG ADMINISTRATION FORM					1 JAN 2008 Version 1.0 Page 3 of 3	
Site:	Screening ID:		Letters:		Visit Date:	/	/_	
	SION RELATED PRO	- <del>-</del>						
<ol> <li>Did the participant experience any problems during study drug administration?</li> <li>If YES,</li> </ol>						Y	N	
	*							
a. S	Specify:							
	If YES, comple	ete an Adverse Even	t Report For	rm (CTL13	) if $\geq$ Grade 2 s	severity.		
	If th	e adverse event is G	Frade 1 reco	rd on source	document.			

Initials (first, middle, last) of person completing this form:

**Date form completed:**